Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | Biomarker | disease | BEFREE | Finally, we explored the therapeutic potential of a combination therapy targeting both TOP2A and EZH2 using novel prostate cancer-derived murine cell lines.<b>Results:</b> We demonstrate by genome-wide analysis of independent primary and metastatic prostate cancer datasets that concurrent TOP2A and EZH2 mRNA and protein upregulation selected for a subgroup of primary and metastatic patients with more aggressive disease and notable overlap of genes involved in mitotic regulation. | 28899973 | 2017 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | EZH2 is overexpressed in metastatic prostate cancer and has been shown to promote cell proliferation and metastasis. | 25341040 | 2014 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. | 23636686 | 2013 | ||||
|
0.090 | Biomarker | disease | BEFREE | Exploring GEO and Oncomine databases, we found that specific PRC2 genes (EED, EZH2, SUZ12) predict poor prognosis in PC. | 21501485 | 2011 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | EZH2 mRNA expression density in the metastatic prostate cancer group was significantly higher than in the control (p=0.023) and localized prostate cancer groups (p=0.019). | 18159594 | 2007 | ||||
|
0.090 | Biomarker | disease | BEFREE | We demonstrate that in multiple experimental models of metastatic prostate cancer both BMI1 and Ezh2 genes are amplified and gene amplification is associated with increased expression of corresponding mRNAs and proteins. | 16963837 | 2006 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | Recent experiments have demonstrated that the Polycomb group (PcG) gene EZH2 is highly expressed in metastatic prostate cancer and in lymphomas. | 14532106 | 2003 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? | 12450788 | 2002 | ||||
|
0.090 | Biomarker | disease | BEFREE | Amounts of both EZH2 messenger RNA and EZH2 protein are increased in metastatic prostate cancer; in addition, clinically localized prostate cancers that express higher concentrations of EZH2 show a poorer prognosis. | 12374981 | 2002 |